GSK licenses Ionis' midphase hepatitis B program for $25M

GlaxoSmithKline has licensed Ionis Pharmaceuticals’ antisense hepatitis B medicines for $25 million. The deal, which is part of the long-running relationship between the companies, comes shortly after GSK achieved clinical proof of concept for the Ionis-partnered hepatitis B program.